IMVT
IMVT
NASDAQ · Biotechnology

Immunovant Inc

$24.76
+0.92 (+3.86%)
As of Mar 25, 9:51 PM ET ·
Financial Highlights (FY 2025)
Revenue
1.40B
Net Income
261.90M
Gross Margin
31.8%
Profit Margin
18.7%
Rev Growth
+1.7%
D/E Ratio
0.75
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 31.8% 31.8% 31.8%
Operating Margin 19.6% 19.0% 22.1%
Profit Margin 18.7% 23.6% 19.4%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 1.40B 1.44B 1.30B
Gross Profit 445.67M 457.51M 414.52M
Operating Income 274.42M 272.52M 287.15M
Net Income 261.90M 339.04M 251.92M
Gross Margin 31.8% 31.8% 31.8%
Operating Margin 19.6% 19.0% 22.1%
Profit Margin 18.7% 23.6% 19.4%
Rev Growth +1.7% -7.0% +15.8%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 2.23B 2.28B 2.03B
Total Equity 2.96B 3.29B 3.14B
D/E Ratio 0.75 0.69 0.65
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA 403.28M 390.65M 352.93M
Free Cash Flow 259.22M 284.01M 237.35M